Tag #Drug Discovery

Showing 25 to 27 of 27 results

repubblica.it

🌐 95% Global Worthiness

Dec 13, 16:13

Italian Researcher's Open-Source AI Rivals DeepMind's AlphaFold3

Gabriele Corso, a 25-year-old Italian researcher at MIT, developed Boltz-1, an open-source AI model for analyzing molecular interactions with accuracy matching DeepMind's AlphaFold3, revolutionizing drug discovery by making advanced AI accessible to researchers worldwide.

Italian Researcher's Open-Source AI Rivals DeepMind's AlphaFold3

Gabriele Corso, a 25-year-old Italian researcher at MIT, developed Boltz-1, an open-source AI model for analyzing molecular interactions with accuracy matching DeepMind's AlphaFold3, revolutionizing drug discovery by making advanced AI accessible to researchers worldwide.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does Gabriele Corso's latest AI model, Boltz-1, compare to existing solutions, and what is its impact on drug discovery?

Gabriele Corso's open-source AI model, Boltz-1, matches AlphaFold3's accuracy but offers global accessibility, unlike DeepMind's proprietary model. This allows thousands of researchers and pharmaceutical companies to use it for faster and cheaper drug discovery. His previous model, DiffDock, is already used widely in the industry.

smh.com.au

🌐 85% Global Worthiness

Nov 29, 11:25

AI-Developed Drug Shows Promise in Cardiovascular Disease Treatment

Algorae Pharmaceuticals' AI-168 drug combination, partly involving cannabidiol, has shown significant promise in pre-clinical in-vitro studies to improve on existing treatments for cardiovascular disease, outperforming beta-blockers in three cell line models and leading to an international patent ap...

AI-Developed Drug Shows Promise in Cardiovascular Disease Treatment

Algorae Pharmaceuticals' AI-168 drug combination, partly involving cannabidiol, has shown significant promise in pre-clinical in-vitro studies to improve on existing treatments for cardiovascular disease, outperforming beta-blockers in three cell line models and leading to an international patent ap...

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of Algorae Pharmaceuticals' AI-168 drug combination for cardiovascular disease treatment?

Algorae Pharmaceuticals announced that its AI-developed drug combination, AI-168, shows promise in protecting the heart from cardiovascular stressors. Pre-clinical in-vitro studies demonstrated significant improvements (94%, 80%, and 68% respectively) in three cell line models compared to existing beta-blockers. An international patent application has been filed.

parma.repubblica.it

🌐 75% Global Worthiness

Dec 10, 22:09

€400,000 Grant Funds Multi-Omic Leukemia Therapy Research at University of Parma

The University of Parma's Translational Hematology and Chemogenomics group received a €400,000 grant to develop personalized therapies for high-risk acute leukemias using a multi-omic model integrating genomic, proteomic, and metabolic data, led by Giovanni Roti in collaboration with Alessio Lodola.

€400,000 Grant Funds Multi-Omic Leukemia Therapy Research at University of Parma

The University of Parma's Translational Hematology and Chemogenomics group received a €400,000 grant to develop personalized therapies for high-risk acute leukemias using a multi-omic model integrating genomic, proteomic, and metabolic data, led by Giovanni Roti in collaboration with Alessio Lodola.

Progress

8% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How will the collaboration between the hematology and drug design experts contribute to the project's success?

The LDRscreen project, a collaboration between Giovanni Roti and Alessio Lodola, leverages advanced technologies in rational drug design. It will develop new platforms for drug repositioning and identify therapeutic targets via genomic, proteomic, and metabolic analysis. This aligns with the THEC's mission to translate academic research into precision medicine.

Showing 25 to 27 of 27 results